Outcomes in Mitral Regurgitation Due to Flail LeafletsA Multicenter European Study
Francesco Grigioni, MD, PhD*,*,
Christophe Tribouilloy, MD, PhD, FACC ,
Jean Francois Avierinos, MD ,
Andrea Barbieri, MD ,
Marinella Ferlito, MD*,
Faouzi Trojette, MD ,
Laurence Tafanelli, MD ,
Angelo Branzi, MD*,
Catherine Szymanski, MD ,
Gilbert Habib, MD ,
Maria G. Modena, MD ,
Maurice Enriquez-Sarano, MD, FACC|| on behalf of the MIDA Investigators
* University Hospital of Bologna, Bolgona, Italy
University of Amiens, Amiens, France
University of Marseille, Marseille, France
University of Modena, Modena, Italy
|| Mayo Clinic, Rochester, Minnesota.
* Reprint requests and correspondence: Dr. Francesco Grigioni, Istituto di Malattie dellApparato Cardiovascolare, Ospedale S. Orsola Malpighi, Via Massarenti 9, 40138 Bologna, Italy. (Email: francesco.grigioni{at}unibo.it).
Objectives: The purpose of this study was to assess incidence and predictors of events associated with nonsurgical and surgical management of severe mitral regurgitation (MR) in European institutions.
Background: The management of patients with MR remains disputed, warranting multicenter studies to define clinical outcome in routine clinical practice.
Methods: The MIDA (Mitral Regurgitation International DAtabase) is a registry created for multicenter study of MR with echocardiographically diagnosed flail leaflet as a model of pure, organic MR. Our cases were collected from 4 European centers. We enrolled 394 patients (age 64 ± 11 years; 67% men; 64% in New York Heart Association functional class I to II; left ventricular ejection fraction 67 ± 10%).
Results: During a median follow-up of 3.9 years, linearized event rates/year under nonsurgical management were 5.4% for atrial fibrillation (AF), 8.0% for heart failure (HF), and 2.6% for death. Mitral valve (MV) surgery was performed in 315 (80%) patients (repair in 250 of 315, 80%). Perioperative mortality, defined as death within 30 days from the operation, was 0.7% (n = 2). Surgery during follow-up was independently associated with reduced risk of death (adjusted hazard ratio [HR] 0.42, 95% confidence interval [CI] 0.21 to 0.84; p = 0.014). Benefit was largely driven by MV repair (adjusted HR vs. replacement 0.37, 95% CI 0.18 to 0.76; p = 0.007). In 102 patients strictly asymptomatic and with normal ventricular function, 5-year combined incidence of AF, HF, or cardiovascular death (CVD) was 42 ± 8%. In these patients, surgery also reduced rates of CVD/HF (HR 0.26, 95% CI 0.08 to 0.89; p = 0.032).
Conclusions: In this multicenter study, nonsurgical management of severe MR was associated with notable rates of adverse events. Surgery especially MV repair performed during follow-up was beneficial in reducing rates of cardiac events. These findings support surgical consideration in patients with MR due to flail leaflets for whom MV repair is feasible.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | CI = confidence interval | | CVD = cardiovascular death | | HF = heart failure | | HR = hazard ratio | | LV = left ventricular | | LVEF = left ventricular ejection fraction | | LVESD = left ventricular end-systolic diameter | | MR = mitral regurgitation | | MV = mitral valve | | NYHA = New York Heart Association |
|
Related articles in JACC Imaging:
- Should We Operate on Asymptomatic Patients With Severe Mitral Regurgitation?
- Paul A. Grayburn
JACC Imaging 2008 1: 142-144.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
P. A. Grayburn
Should We Operate on Asymptomatic Patients With Severe Mitral Regurgitation?
J. Am. Coll. Cardiol. Img.,
March 1, 2008;
1(2):
142 - 144.
[Full Text]
[PDF]
|
 |
|
|